[go: up one dir, main page]

BR9508021A - Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico - Google Patents

Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Info

Publication number
BR9508021A
BR9508021A BR9508021-0A BR9508021A BR9508021A BR 9508021 A BR9508021 A BR 9508021A BR 9508021 A BR9508021 A BR 9508021A BR 9508021 A BR9508021 A BR 9508021A
Authority
BR
Brazil
Prior art keywords
schizophrenic
treatment
pharmaceutical composition
immunosuppressive agent
pct
Prior art date
Application number
BR9508021-0A
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR9508021A publication Critical patent/BR9508021A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO DE DISTúRBIOS ESQUIZOFRêNICOS, USO DE UM AGENTE IMUNOSSUPRESSOR, E, PROCESSO DE TRATAMENTO DE UM PACIENTE ESQUIZOFRêNICO". A presente invenção refere-se a uma composição farmacêutica para o tratamento de distúrbios esquizofrênicos a qual compreende um veículo farmaceuticamente aceitável e um agente imunossupressor como ingrediente ativo.
BR9508021-0A 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico BR9508021A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia
PCT/EP1995/002289 WO1995034306A1 (en) 1994-06-13 1995-06-13 Use of immunosuppressive agents for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BR9508021A true BR9508021A (pt) 2004-04-20

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508021-0A BR9508021A (pt) 1994-06-13 1995-06-13 Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico

Country Status (11)

Country Link
US (1) US5912250A (pt)
EP (1) EP0772442B1 (pt)
JP (1) JPH10501257A (pt)
AT (1) ATE216891T1 (pt)
AU (1) AU704355B2 (pt)
BR (1) BR9508021A (pt)
CA (1) CA2192822C (pt)
DE (1) DE69526584T2 (pt)
ES (1) ES2176331T3 (pt)
IL (1) IL110011A (pt)
WO (1) WO1995034306A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020273A1 (en) * 1997-10-17 1999-04-29 The Rockefeller University Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
CA2531980C (en) 2003-06-23 2013-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imide derivatives as therapeutic agents for senile dementia
US20070160537A1 (en) 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
WO2008008472A2 (en) * 2006-07-13 2008-01-17 President And Fellows Of Harvard College Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
WO1995034306A1 (en) 1995-12-21
AU704355B2 (en) 1999-04-22
AU2881995A (en) 1996-01-05
EP0772442B1 (en) 2002-05-02
CA2192822C (en) 2007-04-03
DE69526584T2 (de) 2002-11-14
IL110011A (en) 2004-09-27
ATE216891T1 (de) 2002-05-15
CA2192822A1 (en) 1995-12-21
JPH10501257A (ja) 1998-02-03
EP0772442A1 (en) 1997-05-14
DE69526584D1 (de) 2002-06-06
ES2176331T3 (es) 2002-12-01
IL110011A0 (en) 1994-10-07
US5912250A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
PT760649E (pt) Formulacoes a base de propionato de fluticasona
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
TW324662B (en) Benzamide-containing pharmaceutical composition
ATE114244T1 (de) Pharmazeutische zusammensetzungen enthaltend fluticasonpropionat und oxikonazol oder dessen salz zur lokalen anwendung.
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
HU9601684D0 (en) Deuterised active agents in transdermal application
BR9506748A (pt) Compostos preparação farmacêutica utilização de um composto e processos para o tratamento de um indivíduo sofrendo de dor e para a preparação de um composto
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
NO984920D0 (no) Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.
BR9406865A (pt) Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica
AU4091597A (en) Sulfonyl fluorides for the treatment of alzheimer's disease
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]